A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma

Trial Profile

A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 18 Sep 2017 Treatment arm has been increased from 3 to 4 and patients number also increases.
    • 18 Sep 2017 Planned number of patients changed from 46 to 50.
    • 18 Sep 2017 Planned End Date changed from 22 Jul 2018 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top